SRP412760 PRJNA911728 GSE220825 The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [tumor RNA-seq] Multiple Myeloma (MM) is a neoplasm of plasma cells originating in the bone marrow and is the second most common blood cancer in the United States. One challenge in understanding the pathogenesis of Multiple Myeloma (MM) and improving treatment is a lack of immunocompetent mouse models. We previously developed the IL6Myc mouse that generates plasmacytomas at 100% frequency that phenotypically resemble aggressive MM. Using comprehensive genomic analysis, we found that the RNA expression patterns between tumors were somewhat heterogenous, but nonetheless resembled MMSET (multiple myeloma SET domain), an aggressive form of human myeloma with poor prognosis. Cell lines derived from the mouse tumors expressed cell-surface markers typical of MM, but also expressed BAFF-R, which is infrequently found in human MM. The cell lines also had heterogeneous responses to chemotherapeutic drugs typically used to treat human MM. Interestingly IL6Myc tumors accumulated variants in genes like those seen in human MM, as well as recurrent Ig translocations, a common characteristic of human MM. These data indicate that the IL6Myc model is a useful model for aggressive MM that can be used to develop treatment and understand how early myc expression influences disease etiology. Overall design: RNA extracted from 7 MLN and Splenic tumors from IL6Myc transgenic mice. Samples for which the numbers are the same indicate that they are tumors from the same mouse. Controls for this study were LPS activated B cells and quiescent B cells from WT Balb/c mice. Prior to RNA isolation all tissue samples were sorted for B cells using negative selection magnetic bead separation. GSE220825 parent_bioproject PRJNA911669